Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 5, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Other endpoints in screening studies for soft tissue sarcomas.

Jaap Verweij1

  • 1Erasmus University Medical Center, Rotterdam, The Netherlands. j.verweij@erasmusmc.nl

The Oncologist
|June 17, 2008
PubMed
Summary

Developing novel therapies for soft tissue sarcomas is critical due to limited treatment options. This review examines current clinical trial endpoints and proposes improved criteria for evaluating new soft tissue sarcoma treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and Potential Solutions to Advance Global Cancer Drug Development.

Therapeutic innovation & regulatory science·2026
Same author

Empowering effective biomarker-driven precision oncology: A call to action.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.

Clinical cancer research : an official journal of the American Association for Cancer Research·2021
Same author

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe.

Cancers·2020
Same author

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.

Breast cancer research and treatment·2019

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Sarcoma Research

Background:

  • Soft tissue sarcomas (STS) have limited effective treatment options, highlighting a significant unmet medical need.
  • Current research has yielded few highly effective agents for STS treatment over the past two decades.
  • Optimizing clinical trial design is crucial for identifying beneficial novel therapies for STS patients.

Purpose of the Study:

  • To discuss the limitations of current clinical trial endpoint criteria used in soft tissue sarcoma research.
  • To explore potential alternative endpoint criteria for evaluating new STS treatment options.
  • To improve the accuracy and relevance of clinical outcome measures in STS trials.

Main Methods:

  • Review of existing literature on clinical trial endpoints for soft tissue sarcomas.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Related Experiment Videos

Last Updated: Jul 5, 2026

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

  • Analysis of the limitations associated with traditional survival endpoints.
  • Evaluation of alternative endpoints such as progression-free survival and time to progression.

    • Main Results:

    • Traditional endpoints like overall survival can be difficult to measure and may not fully capture therapeutic benefit in STS.
    • Physiological and biological markers, while easily measured, can lead to false-positive results.
    • Alternative endpoints like progression-free survival rate, time to progression, tumor growth rate, and progression arrest rate are being explored.

    Conclusions:

    • Current endpoint criteria for soft tissue sarcoma clinical trials have significant limitations.
    • There is a need for more robust and accurate endpoints to better evaluate novel therapeutic agents.
    • Refining endpoint selection is essential for advancing the development of effective treatments for soft tissue sarcomas.